Skip to search formSkip to main contentSkip to account menu

Associations of T-cell fitness prior to B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T-cell (CART) and bispecific T-cell engager (BiTE) therapies and efficacy/toxicity in…

Overall PSI, CD4+ PSI and CD8+ PSI were 1.1 times higher in R compared to NR and overall PSI was slightly higher in CRS/ICANS compared to no CRS/ICANS though the difference was not statistically significant.
Publisher (opens in a new tab)

P-088 Evaluating T-cell Fitness Pre B-Cell Maturation Antigen (BCMA)-Targeted T-Cell Redirection Therapies (TRT) as a Predictive Marker for Efficacy/Toxicity in Relapsed/Refractory Multiple Myeloma…

Publisher (opens in a new tab)

Abstract

Chemotherapy has shown to mitigate the poor prognosis associated with EATL in this study and is a rare subtype of non-Hodgkin lymphoma.
Wiley (opens in a new tab)

Open-label, single-arm phase Ib/II study of immune combination therapy with elotuzumab and belantamab mafodotin in patients with relapsed refractory multiple myeloma.

This novel combination immune therapy with belantamab mafodotin and elotuzumab appears to have an encouraging safety profile and a promising preliminary efficacy in patients with heavily pretreated RRMM, including in those with prior failure of BCMA-targeted therapy.
Publisher (opens in a new tab)
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)